Advised Virax Biolabs Group Limited in its Initial Public Offering On the Nasdaq Capital Market

Represented the biotechnology company Virax Biolabs Group Limited, as issuer counsel, in its initial public offering of 1,350,000 ordinary shares at a price of $5.00 per share on the Nasdaq Capital Market under the ticker symbol “VRAX.”